Alnylam Pharmaceuticals, Inc.
ALNY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $30,038 | $23,908 | $28,919 | $20,087 |
| - Cash | $966 | $813 | $866 | $820 |
| + Debt | $1,296 | $1,305 | $1,320 | $998 |
| Enterprise Value | $30,367 | $24,401 | $29,373 | $20,265 |
| Revenue | $2,248 | $1,828 | $1,037 | $844 |
| % Growth | 23% | 76.2% | 22.9% | – |
| Gross Profit | $1,925 | $1,518 | $869 | $704 |
| % Margin | 85.6% | 83% | 83.7% | 83.4% |
| EBITDA | -$179 | -$258 | -$927 | -$662 |
| % Margin | -8% | -14.1% | -89.3% | -78.4% |
| Net Income | -$278 | -$440 | -$1,131 | -$853 |
| % Margin | -12.4% | -24.1% | -109% | -101% |
| EPS Diluted | -2.18 | -3.52 | -9.3 | -7.2 |
| % Growth | 38.1% | 62.2% | -29.2% | – |
| Operating Cash Flow | -$8 | $104 | -$541 | -$642 |
| Capital Expenditures | -$34 | -$62 | -$72 | -$76 |
| Free Cash Flow | -$43 | $42 | -$613 | -$718 |